Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | DPYD | Q12882 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4394661 | 1.00 | GAA (0.45) | GAADPYDLMNAMAPTALDH1A1 | |
| SCHEMBL1210894 | 0.78 | GAA (0.50) | GAADPYDLMNAMAPTALDH1A1 | |
| SCHEMBL29908302 | 0.77 | GAA (0.45) | GAADPYDLMNAMAPTALDH1A1 | |
| SCHEMBL16703602 | 0.76 | GAA (0.48) | GAADPYDLMNAMAPTALDH1A1 | |
| SCHEMBL127493 | 0.71 | KDM3B (0.64) | GAADPYDLMNAMAPTALDH1A1 | |
| SCHEMBL6524027 | 0.69 | GAA (0.50) | GAADPYDLMNAMAPTALDH1A1 | |
| SCHEMBL190958 | 0.69 | GAA (0.50) | GAADPYDLMNAMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL11439523 | 0.69 | KDM3B (0.62) | GAADPYDLMNAMAPTALDH1A1 | |
| Water SCHEMBL4487821 | 0.69 | KDM3B (0.62) | GAADPYDLMNAMAPTALDH1A1 | |
| SCHEMBL933035 | 0.68 | DPYD (0.48) | GAADPYDLMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373264-B1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-6821972-B2 | ANTISCARRING AGENTS; WOUND HEALING AGENTS; ENZYME INHIBITORS | PFIZER INC. | 2004-11-23 | — | — | US | disclosed |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PFIZER INC. | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PAH, CYP2F1, CYP7A1 | GAA 2209/4885DPYD 149/4885LMNA 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.